Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brand Companies Will “Lose Interest” In Generic Divisions, Watson Predicts

This article was originally published in The Pink Sheet Daily

Executive Summary

Watson expects history to repeat itself as brand name manufacturers experiment with in-house generic drug divisions

You may also be interested in...



J&J Going Generic? McNeil “Exploratory Project” May Pave The Way

“Patriot” division is appearing at trade shows in an “intelligence-gathering” capacity, McNeil says. An in-house generic operation would provide J&J with a greater share of profits than “authorized” generic deals.

J&J Going Generic? McNeil “Exploratory Project” May Pave The Way

“Patriot” division is appearing at trade shows in an “intelligence-gathering” capacity, McNeil says. An in-house generic operation would provide J&J with a greater share of profits than “authorized” generic deals.

Mylan's Legal Fight Against "Authorized" Generics May Shift To Antitrust Attack

Generic firm dismisses lawsuit against FDA seeking a preliminary injunction related to Watson's marketing of a Macrobid "authorized" generic. Dismissal comes shortly before a W.Va. federal judge was expected to rule on claims under the FD&C Act and Administrative Procedures Act. Mylan could revive its lawsuit through antitrust claims.

Related Content

Topics

UsernamePublicRestriction

Register

PS060671

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel